A Study in First-Episode Psychosis Patients: Does Angiotensin I-Converting Enzyme Activity Associated With Genotype Predict Symptom Severity Reductions After Treatment With Atypical Antipsychotic Risperidone?

Author(s):Show less -

Nani, V, Joao ; Dal Mas, Caroline ^[1] ; Yonamine, Camila M. ^[1] ; Ota, Vanessa K. ^[2] ; Noto, Cristiano ^{[3, 4]} ; Belangero, I, Sintia ; Mari, Jair J. ^[3] ; Bressan, Rodrigo ^[3] ; Cordeiro, Quirino ^[4] ; Gadelha, Ary ^[3] ; Hayashi, Mirian A. F. ^{[1, 5]}

Affiliation

^[1] Nani, Joao, V, Univ Fed Sao Paulo UNIFESP, Dept Pharmacol, Sao Paulo - Brazil

^[2] I, Univ Fed Sao Paulo UNIFESP, Dept Genet, Sao Paulo - Brazil

^[3] Nani, Joao, V, Univ Fed Sao Paulo UNIFESP, Dept Psychiat, Sao Paulo - Brazil

^[4] Univ Fed Sao Paulo UNIFESP, First Episode Psychosis Program, Sao Paulo - Brazil

^[5] Nani, Joao, V, CNPq, Natl Inst Translat Med INCT TM, Ribeirao Preto - Brazil

• Document type: Journal article
• Source: INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY; v. 23, n. 11, p. 721-730, NOV 2020.
• Web of Science Citations: 0

Abstract

Background: Our previous studies showed increased angiotensin I-converting enzyme (ACE) activity in chronic schizophrenia patients compared with healthy control (HC) volunteers, and the relevance of combining ACE genotype and activity for predicting schizophrenia was suggested. Methods: ACE activity was measured in plasma of ACE insertion/deletion (I/D) genotyped HC volunteers (n = 53) and antipsychotic-naive first-episode psychosis (FEP) patients (n = 45) assessed at baseline (FEB-B) and also after 2 months (FEP2M) of treatment with the atypical antipsychotic risperidone. Results: ACE activity measurements showed significant differences among HC, FEP-B, and FEP-2M groups (F = 5.356, df = 2, P =.005) as well as between HC and FEP-2M (post-hoc Tukey's multiple comparisons test, P =.004). No correlation was observed for ACE activity increases and symptom severity reductions in FEP as assessed by total Positive and Negative Syndrome Scale (r = -0.131, P =.434). FEP subgrouped by ACE I/D genotype showed significant ACE activity increases, mainly in the DD genotype subgroup. No correlation between ACE activity and age was observed in FEP or HC groups separately (r = 0.210, P =.392), but ACE activity level differences observed between these groups were influenced by age. Conclusions: The importance of measuring the ACE activity in blood plasma, associated with ACE I/D genotyping to support the follow-up of FEP patients, did not show correlation with general symptom amelioration in the present study. However, new insights into the influence of age and I/D genotype for ACE activity changes in FEP individuals upon treatment was demonstrated. (AU)

• FAPESP's process: 17/25016-8 - Investigation of the treatment response of schizophrenia with risperidone: a pharmacogenetics study in a cohort of first episode of psychosis patients
• Grantee: Síntia Iole Nogueira Belangero
• Support Opportunities: Regular Research Grants
• FAPESP's process: 17/02413-1 - Validation of crotamine as a biomarker and evaluation of its potential use in the therapy of human diseases
• Grantee: Mirian Akemi Furuie Hayashi
• Support Opportunities: Regular Research Grants
• FAPESP's process: 12/08941-6 - The study of oligopeptidases in schizophrenia
• Grantee: Camila Miyagui Yonamine Asanuma
• Support Opportunities: Scholarships in Brazil - Post-Doctoral
• FAPESP's process: 19/09207-3 - Study of molecular and cellular mechanisms in mental disorders
• Grantee: João Victor Silva Nani
• Support Opportunities: Scholarships in Brazil - Doctorate